




Saamya Biotech (India) Ltd.

7th Annual Report 2008-09





BOARD OF DIRECTORS	Mr. C. CHANDRASEKHAR REDDY	Chairman
	Dr. Y. MANIVARDHAN REDDY	Managing Director
	Dr. Y. SONIA REDDY	Vice Chairman & Joint Managing Director
	Dr. K. NARAYANA REDDY	Technical Director
	Dr. ASHOK KUMAR SADHUKHAN	Technical Director
	Dr. P. NAVEEN CHANDER REDDY	Independent Director
	Mr. G. YESHWANTH REDDY	Independent Director
	Mr. P. SURESH REDDY	Independent Director
	Dr. C. NAVEEN REDDY	Additional Director

BANKERS	1. SYNDICATE BANK, Somajiguda Branch, Hyderabad. 2. INDIAN OVERSEAS BANK, Hyderabad Main Branch 3. THE LAKSHMI VILAS BANK, Bank Street, Hyderabad
----------------	---

AUDITORS	M/s P. MURALI & CO, CHARTERED ACCOUNTANTS 6-3-655/2/3, SOMAJIGUDA, HYDERABAD- 500 082 PHONE: 040-2332 6666 Fax: 040-2339 2474
-----------------	--

REGISTERED OFFICE	SUITE NO. 104-106, LUMBINI ENCLAVE, PANJAGUTTA, HYDERABAD –500 082 Phone:040-2339 9241 Fax: 040-2339 5214 email: info@saamyabiotech.com website: www.saamyabiotech.com
--------------------------	---

CORPORATE OFFICE	PLOT NO.391D, ROAD NO.81 JUBILEE HILLS HOUSE BUILDING SOCIETY, PHASE III, JUBILEE HILLS HYDERABAD - 500 096 PHONE: 040-2355 1601/04 FAX: 040-2354 1127
-------------------------	---

SHARE TRANSFER AGENTS	M/s AARTHI CONSULTANTS PRIVATE LIMITED 1-2-285, DOMALGUDA, HYDERABAD – 500 029. Tel: +91-40-2763 4445, 2763 8111, 2764 2217 Fax: +91-40-2763 2184,
----------------------------------	---

LISTED AT	BOMBAY STOCK EXCHANGE LIMITED (BSE), MUMBAI
------------------	--



CHAIRMAN'S MESSAGE

Dear Shareholders,

Your Company has made the desired progress in its path of achieving the cherished goals in 2008-09 and this has been possible by the unshaken commitment and dedicated efforts of your Board of Directors and the management team in the climate of intense global recession. The expansion plans conceived by your company have registered marked progress despite the various recession linked hurdles.

The additional funds required for executing the expansion plans of your company's business have been secured from Indian Overseas Bank and the funds are put in place to facilitate the project implementation on practical schedules.

You will be delighted to note that your company is constantly exploring novel and efficient technologies and now, your company has successfully sourced a better technology with higher yields and purity for the products in its manufacturing portfolio and is well poised to acquire this technology from Europe which contributes to higher value and profitability of your company.

Another significant achievement is that your company took a strategic move towards increasing net worth of the company and profitability by planning to acquire a functioning and profit making synthetic drug manufacturing company in Hyderabad. This is an important step leading to value addition to your company by way of manufacturing very high value hemi synthetic drugs from the products produced from the biotech plant, in addition to manufacturing high value synthetic drug products. The funds required for acquiring this company are secured from Lakshmi Vilas Bank.

On the front of your subsidiary company registered in Malaysia in the name of Saamy Biotech (Malaysia) Sdn. Bhd., all the clearances, incentives and grants from Malaysian Industrial Development Authority (MIDA) have been obtained and Perak State Government has offered equity participation through land contribution for the company. Your company is also considering another offer from BioXcel Group of Malaysian Biotechnology Corporation,



a Federal Government Agency of Malaysia to support the Malaysian project for manufacturing high value biopharmaceuticals through provision of " Built to lease facility" in Johar State of Malaysia at a location near to Singapore.

I am happy that your company has registered good progress in its path of achieving the objectives and I take pleasure in rededicating my efforts along with my colleagues on the Board to take your company to heights of success and enable you to reap the fruits at the earliest.

I wish to thank all our well wishers, stakeholders, collaborators, Bankers and employees of the company for extending their full support and cooperation all through the year.

A handwritten signature in black ink that reads 'C. C. Reddy'.

C. C. Reddy
Chairman

Place: Hyderabad

Date: 31st August, 2009



NOTICE

NOTICE is hereby given that the **SEVENTH** Annual General Meeting of the Members of SAAMYA BIOTECH (INDIA) LIMITED will be held on Wednesday, the 30th September 2009 at 4.00 P.M. at Sundaraiah Vignana Kendram, (Mini Hall), Bagh Lingampally, Hyderabad - 500 044 to consider the following Business:

ORDINARY BUSINESS

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March 2009 and Cash Flow Statement as on that date along with the Reports of the Directors and the Auditors thereon.
2. To appoint a Director in place of **Dr. Ashok Kumar Sadhukhan**, who retires by rotation and being eligible, offers himself for re-appointment.
3. To appoint a Director in place of **Dr. P. Naveen Chander Reddy**, who retires by rotation and being eligible, offers himself for re-appointment.
4. To appoint **M/s P. Murali & Co.**, Chartered Accountants, Hyderabad be and are hereby appointed as Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the next Annual General Meeting and to authorize the Board of Directors to fix their remuneration.

SPECIAL BUSINESS

5. **To consider and if thought fit with or without modification, the following resolution as an Ordinary Resolution:**

“RESOLVED THAT Dr. C. Naveen Reddy who was appointed as an Additional Director of the Company on 31st December, 2008 and who is eligible to hold Office up to the date of this Annual General Meeting under Section 260 of the Companies Act, 1956, and in respect of whom the Company has received a notice under Section 257 of the Companies Act, 1956, be and is hereby appointed as a Director of the Company, whose period of office shall be liable to determination by retirement of Directors by rotation.”

BY THE ORDER OF BOARD

Dr. Y. MANIVARDHAN REDDY
MANAGING DIRECTOR

PLACE: HYDERABAD
DATE : 31-08-2009

NOTES

1. A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. PROXIES, TO BE EFFECTIVE, MUST BE RECEIVED BY THE COMPANY NOT LATER THAN 48 HOURS BEFORE COMMENCEMENT OF THE MEETING.



2. Members are requested to intimate the change of address if any, to the Share Transfer Agents, Aarthi Consultants Private Limited, (Unit: Saamya Biotech (India) Limited), 1-2-285, Domalguda, Hyderabad - 500 029, Andhra Pradesh, India. Members, whose shareholdings are in electronic mode, are requested to send the intimation for change of address to their respective Depository Participants and not to the Company or the Share Transfer Agent.
3. Members desirous of obtaining any information on the Annual Accounts of the Company are requested to write to the company at least 7 working days before the date of the meeting to enable the company for compilation of the required information. Members are requested to bring their copy of the Annual Report at the ensuing Annual General Meeting.
4. Corporate Members intending to send their authorized representatives to attend the meeting are requested to send a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the meeting.
5. The Register of the Members and Share Transfer Books of the Company will be closed from Friday, 25th September, 2009 to Wednesday, the 30th September, 2009 (both days inclusive).
6. Members attending the Meeting are requested to complete and bring the attendance slip enclosed with the Annual Report and hand over the same, duly signed, at the entrance of the meeting hall.
7. Members who hold shares in dematerialized form are requested to write their Client ID and DP ID Numbers and those who hold shares in physical form are requested to write their Folio Number in the Attendance slip for attending the meeting.

**ADDITIONAL INFORMATION REQUIRED TO BE FURNISHED UNDER THE LISTING AGREEMENT****Brief Details of Directors seeking reappointment at this Annual General Meeting (Pursuant to Clause 49 of the Listing Agreement)**

Name of the Director	Dr. Ashok Kumar Sadhukhan	Dr. P. Naveen Chander Reddy	Dr. C. Naveen Reddy
Date of Appointment	02-12-2005	27-12-2007	31-12-2008
Date of Birth	21 st August 1948	12 th August 1965	27 th May, 1976
Qualification	M. Sc, Ph. D (Molecular Biology)	MD (General Medicine)	M.D (Paediatrics)
Expertise in Specific functional areas	Over 32 years of experience in industrial biotechnology in various reputed Bio-pharma Industries. He is the Vice Chairman of All India Biotech Association, Treasurer of 'Federation of Asian Biotech Association' and was Research Council Member of Council of Scientific & Industrial Research (CSIR). He was successful in technology transfer of many Biopharmaceutical projects in the country.	He has over 16 years of experience in Medical Profession and is specialized in cardiology. He held senior executive positions in different institutions and hospitals.	He has vast experience in Medical profession. He is a professor in Medici Institute of Medical Sciences. He is panel Doctor to NRSA. He held different positions in institutions and hospitals.
List of Companies in which Directorships held as on 31.03.2009	NIL	NIL	NIL
Chairman/Member of the Committees of other Companies in which he is a Director as on 31.03.2009	NIL	NIL	NIL



Explanatory Statement

[Pursuant to Section 173(2) of the Companies Act, 1956]

Item No: 6

Dr. C. Naveen Reddy has been appointed as an Additional Director by the Board in their Board Meeting held on 31st December, 2008. In terms of section 260 of the Companies Act, 1956, he holds office as such only up to the date of this Annual General Meeting. The company has received a notice in writing under section 257 of the Companies Act, 1956, along with a deposit from a member signifying his intention to propose his name for candidature to the office of Director.

The brief profile of Dr. C. Naveen Reddy has been given elsewhere in this Notice.

The Board recommends the Resolution for the members' approval in the Annual General Meeting.

None of the Directors are directly or indirectly concerned or interested in this resolution except to the extent of his shareholding in the company.

BY THE ORDER OF BOARD

Dr. Y. MANIVARDHAN REDDY
MANAGING DIRECTOR

PLACE: HYDERABAD

DATE: 31-08-2009



DIRECTORS' REPORT

To
The Members,
SAAMYA BIOTECH (INDIA) LIMITED

Your Directors have great pleasure in presenting the SEVENTH Annual Report of the company together with the Audited Accounts for the year ended 31st March, 2009.

FINANCIAL INFORMATION

During the reporting period, your company has not commenced its commercial operations; hence, the information on financial performance of the Company could not be provided in the report for the period under review. Your company has initiated the process of project implementation with a revised and modified plan adding therein two more high value products namely Tacrolimus and Rapamycin to the existing proposed products which require redesigning of the plant and engineering structure including civil works. This move of the management resulted in revision of technical collaborations and engineering works with the collaborators who have shown their interest in the proposed plans. Your company management is confident that once the project is put into commercial operations, the Company will achieve the pre-determined and expected goals.

COMPANY OVERVIEW

The main objective of your company is to manufacture and market Biopharmaceuticals and recombinant protein products of medical and industrial importance, and also to discover and develop emerging biotech products of far reaching significance. Your company embarks on developing effective strategies for the production and marketing of high value biopharmaceutical products with special focus on life saving drug entities and to provide them at affordable price.

A) VISION:

To pursue the path of excellence that enables the company to perform research and manufacture of Biotech products that can effectively meet the challenges posed by the changing medical needs over time of all sections of human populations following cost effective strategies.

B) MISSION:

- To emerge as a Global leader in the discovery, development and manufacture of biopharmaceuticals and recombinant protein products of medical and industrial importance.
- To set up and establish world-class facilities with the necessary infrastructures for research and production of Biotechnology products required to improve the health and quality of human life.
- To develop effective and innovative strategies for the production and supply of Biopharmaceuticals at affordable price.



- To adhere strictly to ethical practices and to emerge as a respectable company with respect to quality of products, services and human relations.
- To recognize the value of shareholders and to reward them amply with short turnaround time as the company sustains growth.

C) STRATEGY:

Your Company's strategy is to lay immediate focus on the means that generate faster revenues with minimal gestation period and ensure sustained growth and racing potential with market leaders, over time. The following actions are planned as part of this strategy.

- To outsource commercially proven technologies for the manufacture of high value biopharmaceutical products that can be quickly implemented in the plant.
- To ensure profitable and total marketing of all the products manufactured in the plant through a marketing tie-up with a firm having proven track record.
- To ensure easy market penetration by manufacturing quality products in compliance with cGMP and USFDA standards.
- To setup collaborations with reputed and competent firms in respect of Technology Sourcing, Project implementation, Product marketing, Research partnering etc.
- To concentrate initially on the manufacture of microbial fermentation drug products in the therapeutic sectors of cancer, immunosuppressants, infections, cardiovascular, orthopaedic and metabolic disorders which are less cost intensive in phase I, and subsequently embark on the manufacture of recombinant protein therapeutic products like Erythropoietin, GCSF, tPA etc., and therapeutic monoclonal antibodies which are relatively more cost intensive in phase II.
- To put in intensive efforts in parallel on research projects that are aimed to achieve strain improvement for higher production potential of products, process improvement for enhanced yield and purity of products by economic routes, and discovery & development of novel, effective and innovative drug products that contribute to constant buildup of IPR's.
- To plan acquisition of functioning manufacturing units of synthetic and biotech drugs within the purview of company's objectives and interests in order to manifest value addition.
- To embark on expansion plans of the company in terms of manufacturing more products and setting up more manufacturing units both in India and abroad.

D) BUSINESS

The commercial operation is yet to make its move because of the delays involved in obtaining the Basic Engineering and Detailed Engineering designs and the related construction activities in line with the revision plan of the project involving new additions in the product profile with a view to cover the wide range of products under one roof. The identified products will have lot of demand in the coming years for preparation of anticancer and immunosuppressive drugs available in the market. Some of the raw



materials required for the project are available in the state of Andhra Pradesh at very reasonable price compared to any part of the world. The project once implemented has all the leadership and guidance oriented approach with competence under the expertise of highly intellectual minds. Hence, your Directors expect a bright future for the company in coming years.

PERFORMANCE

In line with the strategic plans envisaged, your company has accomplished the following to date.

- A technical collaboration has been setup with M/s. Biofin Laboratories s.r.l., Italy, a reputed technology development company for fermentation based drugs, for transfer of production technologies originally for two high value drugs namely Daunomycin, an anticancer drug and Hyaluronic acid, an ophthalmic and orthopedic drug.
- In order to achieve improved commercial viability and increased profitability of the project, your company proposed to add to the production plan, two more high value drugs used in organ transplantation therapies and entered into collaborative agreement with M/s. Biofin Laboratories s.r.l., for the technology transfer of these two products. The basic engineering document and designs which were obtained from M/s Biofin Laboratories were used by our consulting Engineers M/s SEMAC Pvt. Ltd., and M/s M. J. Associates, Bangalore for making detailed engineering designs of our project, which are in the final stage of preparation.
- The revised project plan with the additional products has called for an increase in the project cost from Rs. 28 crores to Rs. 68 crores and the additional fund requirement is planned to be met from financial institutions as Term loan. The Term loan got approved from the Indian Overseas Bank.
- A collaborative agreement for turnkey project implementation with M/s. Shapoorji Pallonji and Co., Mumbai, a reputed engineering and construction firm is already in place.
- Civil works related to the construction of Administrative Block and R&D Block at the Company site in S.P. Biotech Park, Shameerpet, Hyderabad are in progress. Civil construction of the plant and other associated buildings will commence shortly.
- Clearance from the A.P. Pollution Control Board for the products was received.
- Sanction for the electrical connection and the extension of electrical line to the site are completed.
- Basic Engineering Designs of the plant were received from our technical collaborator, M/s Biofin Laboratories s.r.l., Italy. These were passed on to our consulting engineers M/s SEMAC Pvt. Ltd., and M/s M. J. Associates, Bangalore for the preparation of Detailed Engineering Designs. The drawings are in the final stage of preparation.
- Your company has setup a marketing collaboration with M/s. Arch Pharmed Labs Ltd., Mumbai, a reputed Pharma company with about Rs. 500 crores annual turnover



having world wide marketing network for marketing all the products of your company to the extent of 100% production.

- Your company has been currently allotted additional 10 acres of land in Phase-III of AP Biotech Park in SEZ area under its expansion plans, on the request made by your company to the State Government for allotment of 50 acres of land.
- Your company is in the final stage of acquiring a synthetic drug manufacturing company in Hyderabad at a cost of Rs. 15 crores to add value addition to your company by way of manufacturing very high value hemi synthetic drugs from the products produced from the biotech plant, in addition to manufacturing high value synthetic drug products. An MOU was entered in this regard. The Techno Economic Viability Study (TEVS) Report on the acquisition proposal prepared by APITCO, a joint venture consultancy firm of AP Govt. and financial institutions has been submitted to The Lakshmi Vilas Bank Ltd., for term loan funding and the approval from the bank has been obtained. Initial marketing activities of the products of this synthetic drug company will be done through M/s Arch Pharmed Labs Ltd. Your company plans to acquire and start commercial production from this synthetic drug plant in the last quarter of this year.
- Under the expansion plan, your company has registered a subsidiary company in Malaysia in the name of Saamya Biotech (Malaysia) Sdn. Bhd. with the objective of manufacturing high value biopharmaceuticals. The project is estimated at a cost of Rs. 120 crores and the requisite funds are planned to be raised from Malaysian Federal Government and financial institutions. All the clearances, incentives and grants from Malaysian Industrial Development Authority (MIDA) have been obtained and Parek State Government has offered equity participation through land contribution for the company. Your company is also considering another offer from BioXcel Group of Malaysian Biotechnology Corporation, a Federal Govt. agency of Malaysia to support the Malaysian project for manufacturing high value biopharmaceuticals through provision of " Built to lease facility" in Johar State of Malaysia at a location near to Singapore.

DIVIDENDS

You are aware that the Company is in the process of implementing the project and no commercial operations have been commenced; your Directors have not recommended any dividend at this Annual General Meeting.

FIXED DEPOSITS

The Company has not accepted any public deposits and, as such, no amount on account of principal or interest on public deposits was outstanding on the date of the Balance sheet.

PARTICULARS OF EMPLOYEES

In pursuance of the provisions of section 217(2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules 1975, the Directors are to report



that no employee was in receipt of remuneration of Rs. 24,00,000/- or more per annum or Rs. 2,00,000/- or more per month where employed for a part of the year

DETAILS IN TERMS OF CLAUSE 41 OF THE LISTING AGREEMENT

Amount raised in Public Issue	The Company has raised Rs.15,01,25,000/- through Initial Public Offer in the year 2007
The amount so far utilized and Investments made.	Out of the proceeds of the IPO, total amount of Rs.1425.20 Lakhs was utilized for project implementation and preliminary expenses including IPO Expenses.
Description of the pending project	The initial plan of the Company was for setting up of manufacturing facilities including R & D and pilot plant facility of low volume and high value active Bio-Pharmaceutical ingredients such as Daunomycin and Hyaluronic acid. The Directors have also identified Tacrolimus and Rapamycin as products higher in demand for development of immunosuppressive drugs which will definitely add value to the company and ultimately to the stakeholders. This new addition to the project demanded review in the engineering design and plan. The Company in consultation with its technical collaborators i.e. Biofin Laboratories s.r.l., Italy who are taking care of basic engineering specifications, and our consulting engineers M/s SEMAC Pvt. Ltd., Bangalore along with M/s M. J. Associates, Bangalore who are taking care of detailed engineering specifications, and turnkey engineering consultants Shapoorji Pallonji & Co Limited, Mumbai is redesigning the civil construction so as to make it suitable for the proposed project in all aspects.
Status of the project	The turnkey engineering consultants Shapoorji Pallonji & Co Limited, Mumbai have commenced the building construction of R & D and Administrative blocks and the factory building and erection of plant & machinery will be shortly initiated as the engineering designs are in the process of finalization in consultation with the technical collaborators i.e. Biofin Laboratories s.r.l. Italy and turnkey engineering consultants Shapoorji Pallonji & Co Limited, Mumbai.
Expected date of commencement of commercial operations	The commercial production will be commenced once the pre-requisite infrastructure is made available as per the revised plans and the construction of Plant is completed in accordance therewith. Your company expects to commence the commercial operations by the end of 2010.



As mentioned above regarding the status of the project, your company has to furnish the details as per Clause 41 (IV) (e) of the Listing Agreement. In this regard your Directors mention the following:

INFORMATION ON DEPLOYMENT OF FUNDS

The necessary steps have been taken to accelerate the implementation process. Since the project cost has gone up due to various factors such as addition of new products, increase in construction material cost, labour cost etc. your company is facing slowdown in progress. In light of the above and to complete the project, your Directors are also exploring various other means of funding to mitigate the escalated cost. As a measure of information to the members, the following in respect of funds is given hereunder:

(Rs. in Lakhs)

S. No	Particulars	Projected deployment of funds	Actual amount spent / utilized
01	Land and site development	80.00	99.02
02	Building and civil works	316.56	193.09
03	Plant and machinery	1220.00	1120.00
04	Technical Know how fee	500.00	188.21
05	Misc. Fixed Assets	50.00	70.05
06	Preliminary and pre-operative expenses	403.61	647.58
07	Contingencies	137.83	—
08	Margin Money for working capital	100.00	—
	Total	2808.00	2317.95

CREDIT FACILITIES:

Your Company has been sanctioned with the term loan of Rs. 44.48 crores and working capital of Rs. 5.30 crores by Indian Overseas Bank for project expansion and also sanctioned the term loan of Rs. 10.00 crores and working capital of Rs.5.60 crores by Lakshmi Vilas Bank for acquiring the synthetic drug manufacturing plant.

ADDITIONAL INFORMATION REQUIRED UNDER SECTION 217(1) (e) OF THE COMPANIES ACT, 1956.

The information in accordance with the provisions of section 217 (1) (e) of the Companies Act, 1956 read with the Companies (Disclosure of particulars in the Report of Board of Directors) Rules, 1988, regarding conservation of energy and technology absorption are not given as the company has not undertaken any manufacturing activity.

Foreign Exchange Earnings and Outgo

During the reporting period, your Company has not earned any foreign exchange. However, the company incurred expenses in foreign exchange to the extent of Rs.122.66 Lakhs.



CORPORATE GOVERNANCE & MANAGEMENT DISCUSSION & ANALYSIS

In line with the recommendation of the Securities Exchange Board of India (SEBI) on Corporate Governance, your company had constituted the Board with optimum combination of Executive and Non Executive and Independent and Non Independent Directors. Your Company also constituted various committees and all steps have taken to comply with the provisions of the Corporate Governance under the Listing Agreement of the Stock Exchanges.

Separate reports on Corporate Governance and Management Discussion & Analysis are being provided as part of Annual Report.

DECLARATION ON CODE OF CONDUCT

Pursuant to provisions of Clause 49 (I) (D) (ii) of the Listing Agreement, a Declaration declaring that all the members of the Board and the Senior Management Personnel of the Company have affirmed compliance with the Code of Conduct of the Company, is forming part of the Corporate Governance Report attached herewith.

LISTING OF SHARES

The Equity Shares of the Company are listed at Bombay Stock Exchange Limited (stock code no. 532905). The Company has paid the annual listing fee for 2009-10.

DIRECTORS

Dr. Ashok Kumar Sadhukhan and Dr. P. Naveen Chander Reddy, Directors of the Company retire by rotation at the forthcoming Annual General Meeting and being eligible, offer themselves for re-appointment.

However, the Board took opportunity to appreciate the contribution of Mr. Boddapaty Anand during his tenure as Director of the Company and accepted his resignation w.e.f.31st December, 2008.

During the year Dr. C. Naveen Reddy, has been appointed as an Additional Director by the Board in their Meeting held on 31st December, 2008.

The Board confirms that none of the Directors of the Company is disqualified from being appointed as Director in terms of clause (g) to sub-section (1) of Section 274 of the Companies Act, 1956 and necessary declarations have been obtained from all the Directors in this regard.

AUDITORS

M/s P.MURALI & CO., Chartered Accountants, the retiring auditors of the Company being eligible offers themselves for reappointment as auditors of the Company. They furnished their eligibility certificate satisfying the provisions of Section of 224(1B) of the Companies Act, 1956 to the Company. The members are hereby requested to reappoint M/s. P.MURALI & CO., Chartered Accountants as the auditors of the company and further authorize the Board of Directors to fix their remuneration.



DIRECTORS RESPONSIBILITY STATEMENT

1. that in the preparation of the Annual Accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
2. that the Directors selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year;
3. The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
4. The Directors prepared the annual accounts on a going concern basis.

PERSONNEL

The relations between the employees and the management, during the year, have been cordial. The Directors wish to thank all the employees for their continued support and co-operation during the year.

ACKNOWLEDGEMENTS

Your Directors would like to express their grateful appreciation for the assistance and co-operation received from investors, Banks, Government authorities, Customers and Vendors during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services of the executives and employees of the company.

For and on behalf of the Board

C. CHANDRASEKHAR REDDY
Chairman

Dr. Y. MANIVARDHAN REDDY
Managing Director

PLACE: HYDERABAD

DATE: 31-08-2009



MANAGEMENT DISCUSSION AND ANALYSIS REPORT

i. Industry Structure and Development:

The importance of India in the field of Biotechnology is manifold. In addition to generating trained manpower and a knowledge base, India is proving to be an ideal setting for manufacturing activities and high-level biotechnology research programs. With the initiatives taken by the government, Indian Biotechnology is poised for a tremendous growth.

The Department of Biotechnology (DBT) was set up under the Ministry of Science and Technology in 1986. This gave a new impetus to the development of biotechnology in India.

The DBT has set up many Centers of Excellence in the country. These centers are responsible for generating skilled manpower as well as supporting R&D efforts of private industries. This has promoted interactions between the academia and the industry which has resulted in several industry houses from the "old industry" and entrepreneur initiatives to take root and grow biotechnology in India.

The Indian Government has evolved bio-safety guidelines and has helped to lay down patent rules. It has also participated in technology transfers and international collaborations.

The growth of biotechnology in India has led to an increase in budgetary allocations, which have gone up by a tremendous amount from 404 million in 1987-88 to 1138 million in 1997-98 and to 2356 million in 2002-03. The center is also planning to introduce additional venture capital funds in line with its Technology Development Fund (TDF) to promote small and medium biotech enterprises.

The Indian government has laid down a decent regulatory framework to approve GM crops and r-DNA products for human health. A proactive government policy allows stem cell research in the country while having in place sound ethical guidelines. The product patent regime will come into force by the year 2005. The second amendment of the Indian Patents Bill was recently cleared by the Parliament, which include a 20-year patent term, emergency provisions and commencement of R&D immediately after the filing of patents. The bill is compatible with the provisions of WTO and TRIPS.

ii. Opportunities and Threats

As the biotechnology industry outpaces traditional pharmaceuticals, the biotechnology leaders are taking top spots from big pharma peers. At the other end, small, emerging biotechnology companies struggle to find funding among risk-averse investors. As biotechnology companies merge and grow, they are rising in the ranks of the top companies overall. Traditional pharmaceutical companies, meanwhile, are partnering with the biotechnology sector to fill dry pipelines and to replace the dwindling blockbusters. Industry analysts believe that the growth of the biotechnology industry will continue to outpace that of pharmaceutical companies.

iii. Outlook for the Industry

According to Wood Mackenzie analysts, the seven largest biotechnology companies are growing at rates faster than the pharmaceutical industry's 9.1% average growth. In his



statement the chairman comments that the company continued to suffer from the depressed state of the biotechnology stock markets in the United States and particularly in the United Kingdom.

Several states have taken their own initiatives in terms of defining their own biotech policies to give an impetus to the industry in this sector and to biotechnology in India as a whole. States like Andhra Pradesh, Karnataka, Maharashtra, Kerala, Tamil Nadu and Himachal Pradesh are developing biotech parks. They are encouraging research activities, establishing links between their research institutions and industry. Several concessions are being offered to the industry in terms of single window clearance, speedy customs clearance, exemption from tax, creation of funds to be used for the incubation of new project, etc.

India is the second largest food producer after China, and thus offers a huge market for biotechnology products. Transgenics of rice, brassica, moonbean, pigeonpea, cotton, tomato and some vegetables like cabbage, cauliflower etc. are already into field trials. Some of these would be ready for large scale production in a few years. Protein-enriched wheat with higher lysine content was planned to be introduced in the farmers' field by 2003-2005. The nutraceuticals market is valued at Rs. 25000-30,000 mn (US \$ 532-638 mn) presently in a study by Ernst and young. Genetically engineered seed market was worth an estimated \$250 million from a total seed market worth US \$ 500 million in 2001. Marine resource development and aqua culture also hold a great potential as India has more than 8000 kilometers of coastline.

Biotechnology thrust areas in India

Specific Area of investment	Est. investment in next 5 years (Rs. Million)
Vaccines	300-400
Diagnostics	500
Bioactive therapeutic proteins	1000
Seeds (Hybrids, GM)	1500
Bio-pesticides	800
Bio-fertilizers	200
Amino acid production	700
Production of specialty bio-chemicals and plastics	1000



REPORT ON CORPORATE GOVERNANCE

In compliance with Clause 49 of the Listing Agreement entered into with the Stock Exchanges, the Company hereby submits the report on the matters as mentioned in the said Clause and practices followed by the Company.

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE

The basic philosophy of corporate governance of the company is to achieve business excellence and enhance shareholders value keeping in view the interest of all stakeholders. The company stands by transparency in all its dealings and strict regulatory compliance.

2. BOARD OF DIRECTORS

- (a) As on March 31, 2009 the Company has optimum combination of executive, non executive, independent and non independent Directors in terms of Clause 49 of the Listing Agreement entered into with the Stock Exchanges. The Company's Board of Directors comprised 9 Directors consisting of Chairman as Non-Executive, 4 Executive or full time Directors and 4 Non Executive Independent Directors.

Out of 4 Executive Directors 2 are Promoters category and 2 are Non-Promoter Directors. The Board is composed in line with Corporate Governance Code. All Independent Directors comply with the requirements of the Listing Agreement for being "Independent Director". The Board composition is as follows;

Name of the Director	Category	Designation
Mr. C. Chandrasekhar Reddy	Non Executive Director	Chairman
Dr. Y. Manivardhan Reddy	Promoter & Executive Director	Managing Director
Dr. Y. Sonia Reddy	Promoter & Executive Director	Vice Chairman & Joint Managing Director
Dr. K. Narayana Reddy	Executive Director	Technical Director
Dr. Ashok Kumar Sadhukhan	Executive Director	Technical Director
Dr. P. Naveen Chander Reddy	Non Executive Independent Director	Director
Mr. G. Yeshwanth Reddy	Non Executive Independent Director	Director
Mr. P. Suresh Reddy	Non Executive Independent Director	Director
Mr. Boddapaty Anand @	Non Executive Independent Director	Director
Dr. C. Naveen Reddy *	Non Executive Independent Director	Director

@ Resigned as Director from the Board on 31st December, 2008.

* Appointed as an Additional Director on 31st December, 2008.



- (b) None of the Directors on the Board is a member of more than 10 committees or chairman of more than 5 committees as specified in Clause 49, across all the companies in which he is a Director. Necessary disclosures regarding committee positions in other public companies as at March 31, 2009 have been made by the Directors.

Name of the Director	Category	No. of Directorships in other Public Companies	No. of Committees positions held in other Public Companies	
			Chairman	Member
Mr. C. Chandrasekhar Reddy	Non Executive Director	2	Nil	Nil
Dr. Y. Manivardhan Reddy	Promoter & Executive Director	Nil	Nil	Nil
Dr. Y. Sonia Reddy	Promoter & Executive Director	2	Nil	Nil
Dr. K. Narayana Reddy	Executive Director	Nil	Nil	Nil
Dr. Ashok Kumar Sadhukhan	Executive Director	Nil	Nil	Nil
Mr. G. Yeshwanth Reddy	Non Executive Independent Director	1	Nil	Nil
Mr. P. Suresh Reddy	Non Executive Independent Director	Nil	Nil	Nil
Dr. P. Naveen Chander Reddy	Non Executive Independent Director	Nil	Nil	Nil
Dr. C. Naveen Reddy*	Non Executive Independent Director	Nil	Nil	Nil
Mr. Boddapaty Anand @	Non Executive Independent Director	2	Nil	Nil

* Appointed as an Additional Director on 31st December, 2008.

@ Resigned as Director from the Board on 31st December, 2008.

- (c) The details of category of Directorship, attendance of Board Meetings and last Annual General Meeting during the year, number of Directorships, Committee Chairmanships and Memberships held by the Directors in other Companies are furnished herewith. Other Directorships do not include alternative Directorships, Directorships of Private Limited Companies, Section 25 Companies and of Companies incorporated outside India. Chairmanship / Membership of Board Committees include only Audit Committee and the Shareholder's Grievance Committee.
- (d) 10 Board Meetings were held during the year 2008-09. Your Company has complied with all the requirements in terms of Listing Agreement and Companies Act, 1956 in respect of Board Meetings. The dates on which the Meetings were held are as follows:

30th April 2008, 31st July 2008, 1st September 2008, 4th September 2008, , 30th September, 2008, 13th October 2008, 23rd October, 2008, 31st December 2008, 29th January 2009, 31st March, 2009



Name of the Director	No. of Board Meetings (during the year 2008-09)		Whether attended last AGM held on 30.09.2008
	Held	Attended	
Mr. C. Chandrasekhar Reddy	10	8	NO
Dr. Y. Manivardhan Reddy	10	10	Yes
Dr. Y. Sonia Reddy	10	9	Yes
Dr. K. Narayana Reddy	10	7	Yes
Dr. Ashok Kumar Sadhukhan	10	8	Yes
Dr. P. Naveen Chander Reddy	10	5	NO
Mr. G. Yeshwanth Reddy	10	5	NO
Mr. P. Suresh Reddy	10	5	NO
Dr. C. Naveen Reddy*	10	2	NA
Mr. Boddapaty Anand@	10	2	Yes

* Appointed as Additional Director on 31st December, 2008

@ Resigned on 31st December, 2008

- (e) The Board meetings are generally held at least once in a quarter, amongst others for consideration of the audited / Un-audited quarterly financial results. Besides this, additional Board meetings are also convened to address the specific requirements of the Company, as and when the need arises. The urgent items, if any, may be approved by passing resolutions through circulation by the Board. Agenda papers along with detailed notes are circulated to the Directors in advance for each of these meetings. All relevant information, as required was placed before the Board from time to time. The minutes of meetings of Board and Committees are circulated to the members of the meeting for their confirmation.
- (f) None of the Non-Executive Directors has any pecuniary or material relationship or transaction with the Company.

Notes:

Dr. C. Naveen Reddy was appointed by the Board as an Additional Director on 31st December, 2008

Mr Boddapaty Anand has resigned as Director from the Board w.e.f. 31st December, 2008.

(g) **Directors seeking re-appointment**

Dr. Ashok Kumar Sadhukhan and Dr. P. Naveen Chander Reddy, who retire by rotation at the forthcoming Annual General Meeting and being eligible offer themselves for reappointment.

During the year Dr. C. Naveen Reddy has been appointed as Additional Director in the Board meeting held on 31st December, 2008 and he holds the office only up to the



date of the ensuing Annual General Meeting of the Company. He is eligible to act as Director on the Board, if he got elected by the members.

(h) **Board Committees**

To enable better management of the affairs of the Company, the Board delegates certain matters to Committees of the Board set up for the purpose. The proceedings of the meetings of the Committees are circulated to the Board.

3. AUDIT COMMITTEE

- (a) The Audit Committee of the company is constituted in line with the provisions of Clause 49 of the Listing Agreement with the Stock Exchanges read with Section 292A of the Companies Act, 1956.
- (b) The brief description of terms of reference of the Audit Committee is as under:
- I. Oversee the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statements are correct, sufficient and credible.
 - II. Recommending the appointment and removal of external auditor, fixation of their audit fee and also approval for repayment for any other services.
 - III Reviewing with management the quarterly and annual financial statements before submission to the Board.
 - IV Reviewing the adequacy of Internal Control Systems and Internal Audit Reports and their compliance thereof etc.
- (c) The Audit Committee meetings are usually held at the registered office of the Company and are usually attended by the Statutory Auditors, Manager (F&A) apart from Committee members, other functional heads and special invitees to the meetings, as required. The Company Secretary acts as Secretary of the Committee.
- (d) The Chairman of the Audit Committee has attended the previous Annual General Meeting of the Company held on 30th September, 2008 in terms of Clause 49.
- (e) The composition of the Audit Committee and particulars of meetings during the year 2008-09 attended by the members of the Audit Committee are given below:

Name of the Director	Status in the Committee	No. of Meetings	
		Held	Attended
Dr. P. Naveen Chander Reddy@	Chairman	5	5
Mr. P. Suresh Reddy	Member	5	4
Dr. C. Naveen Reddy \$	Member	5	1
Mr Boddapaty Anand*	Chairman	5	4

\$ Dr. C. Naveen Reddy has been appointed as an Additional Director and member of the Audit Committee w.e.f 31st December, 2008



* Mr. Boddapaty Anand has resigned from the Board as Director W.e.f 31st December, 2008.

@ Dr. P. Naveen Chander Reddy has been appointed as Chairman of the Audit Committee w.e.f. 31st December, 2008.

(g) Composition, Meetings & Attendance during the year

The Audit Committee comprises of 3 Non Executive Independent Directors.

5 Audit Committee Meetings were held during the year 2008-09. The dates on which the Meetings were held are as follows:

30th April 2008, 31st July 2008, 31st August, 2008, 23rd October, 2008, 29th January, 2009

The Meetings of the Audit Committee were attended by the Head of Finance and Auditors as Invitees. The Quarterly and Annual audited financials of the Company were reviewed by the Audit Committee before consideration and approval by the Board of Directors. The Committee reviewed the adequacy of Internal Control Systems and the various compliances.

4. REMUNERATION COMMITTEE

Remuneration Committee comprises Non Executive Independent Directors only. The terms of references of the Committee includes recommendations to the Board about Compensation and Benefits for Executive Directors, approval of stock options to employees and such other matters as may be referred to it by the Board from time to time. This Committee consists of the following Independent Directors.

Name of the Director	Status in the Committee	No. of Meetings	
		Held	Attended
Dr. P. Naveen Chander Reddy@	Chairman	1	1
Mr. P. Suresh Reddy	Member	1	1
Dr. C. Naveen Reddy \$	Member	0	0
Mr Boddapaty Anand*	Chairman	1	1

* Mr Boddapaty Anand has resigned from the Board as Director W.e.f 31st December, 2008

\$ Dr. C. Naveen Reddy has been appointed as an Additional Director and member of the Remuneration Committee w.e.f 31st December, 2008.

@ Dr. P. Naveen Chander Reddy has been appointed as Chairman of the Remuneration Committee w.e.f.31st December, 2008.



Directors' Remuneration Policy

Non Executive Directors are not paid any remuneration or sitting fee for the meetings attended by them. There are no performance linked incentives payable to any of the Directors. At present, the company does not have any stock option plan as part of remuneration package for any Director.

Remuneration of the Executive Director comprises of fixed component only.

Details of Remuneration and sitting fee paid during the year are given below:

Name of the Director	Relationship with other Directors	Business relationship with Company if any	Loans and advances from Company	Remuneration Paid During 2008-09 (Rs. in Lakhs)			
				Sitting fees	Salary	Commission	Total
Dr. Y. Manivardhan Reddy	Husband of Dr. Y. Sonia Reddy	Promoter Director	NIL	NIL	18.00	NIL	18.00
Dr. Y. Sonia Reddy	W/o Dr. Y. Manivardhan Reddy	Promoter Director	NIL	NIL	9.00	NIL	9.00
Dr. K. Narayana Reddy	None	Executive Director	NIL	NIL	16.40	NIL	16.40
Dr. Ashok Kumar Sadhukhan	None	Executive Director	NIL	NIL	16.10	NIL	16.10

5. SHAREHOLDERS'/ INVESTORS' GRIEVANCE COMMITTEE

Constitution and Composition

Shareholders'/ Investors' grievance committee has been constituted to look into and redress the grievances of the shareholders and investors pertaining to transfer of shares, non-receipt of Annual Reports etc.

Name of the Member	Status in the Committee	Category
Dr. Ashok K Sadhukhan	Chairman	Executive Director
Dr. C. Naveen Reddy \$	Member	Non Executive and Independent
Dr. P. Naveen Chander Reddy	Member	Non Executive and Independent
Mr. Boddapaty Anand*	Chairman	Non Executive and Independent

* Mr. Boddapaty Anand has resigned from the Board as Director W.e.f 31st December, 2008

\$ Dr. C. Naveen Reddy has been appointed as an Additional Director and member of the Shareholders'/ Investors' grievance committee w.e.f 31st December, 2008.



(ii) The Name and Designation of Compliance Officer

Mr P. Lokeswara Reddy, Manager (Finance & Admn), 104-106, Lumbini Enclave, Punjagutta, Hyderabad-500 082.

(iii) No. of Shareholders' Complaints received during the year 2008-09 and the Status of Investor's Requests/ Complaints as following;

During the year 2008-09 the Company had received 24 requests for various aspects as mentioned below and no complaints have been received during the year.

INVESTOR GRIEVANCE REPORT FOR THE PERIOD 01.04.2008 TO 31.03.2009				
Sl.	Particulars	Received	Resolved	Pending
1	Non receipt of Shares / Refund Orders / Correction of Shares	24	24	Nil
	TOTAL	24	24	Nil

No. of Complaints pending at the beginning of the year : NIL

No. of complaints received but not resolved : NIL

No. of complaints pending at the end of the year : NIL

6. SUBSIDIARY COMPANIES

The Company has no material non listed Indian Subsidiary Company and, therefore, the requirement of inducing an Independent Director on the Board of Directors of the Subsidiary Company does not arise.

7. DISCLOSURES

- a) **Related Party Transactions:** There were no materially significant related party transactions having potential conflict with the interests of the Company at large.
- b) **Accounting Treatment:** There is no different Accounting treatment from the prescribed Accounting standards.
- c) **Risk Management:** The Board regularly discusses the significant business risks identified by the management and the mitigation process being taken up. A detailed note on the risk identification and mitigation is included in Management Discussion and Analysis, annexed to the Directors' Report.
- d) **Strictures and Penalties:** There has not been any non-compliance by the Company and there are no penalties, strictures imposed on the Company by Stock Exchange or SEBI or any statutory authority, on any matter related to capital markets, during the last three years.
- e) **Code of Conduct:** The Board of Directors have laid down a "Code of Conduct" (Code) for all the Board members and the senior management of the Company, and the Code have been posted on the website of the Company. Annual declaration is obtained from every person covered by the Code.
- g) **CEO and Head of Finance Certification:** The CEO and Head of Finance have given certificates to the Board as contemplated in Clause 49 of the Listing Agreement.



- h) **Mandatory Requirements:** All the Mandatory requirements as to Corporate Governance have been complied with.
- i) **Secretarial Audit:** Secretarial Auditor carried out Secretarial Audit to reconcile the total admitted capital with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) and the total issued and listed capital. The Secretarial Audit Report confirms that the total issued / paid up capital is in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL. The Secretarial Audit Report submitted to Stock Exchanges for every quarter within 15 days from the end of the quarter.

8. MEANS OF COMMUNICATION

As per the listing requirements, the company publishes periodical financial results in leading English and Regional Newspapers.

9. PAST THREE ANNUAL GENERAL MEETINGS

- (i) Location and time, where last three AGM's were held:

Year	Location	Date	Time
2007-08	Sundaraiah Vignana Kendram , (Mini Hall), Bagh Lingampally, Hyderabad - 500 044	30th September, 2008	4.00.P.M
2006-07	104-106, Lumbini Enclave, Punjagutta, Hyderabad -500 082.	29th September, 2007	11.00. A.M
2005-06	104-106, Lumbini Enclave, Punjagutta, Hyderabad -500 082.	29th September, 2006	11.00. A.M

- (ii) 6 Special Resolutions have been passed in the previous Annual General Meeting:
- a. To increase the remuneration of Dr. Y. Manivardha Reddy.
 - b. To increase the remuneration of Dr. K. Narayana Reddy.
 - c. To fix the remuneration of Dr. Ashok Kumar Sadhukhan.
 - d. To appoint Dr. Y. Sonia Reddy as Vice-Chairman and Joint-Managing Director of the Company.
 - e. To fix the remuneration of Dr. Y. Sonia Reddy, Vice-Chairman and Joint-Managing Director of the Company.
 - f. To maintain the Register of Members & Debenture holders and index thereof and copies of returns in terms of Section 159 and 160 of the Companies Act, 1956 with M/ s. Aarthi Consultants Private Limited, Registrars and Share Transfer Agents of the Company.
- (iii) One Resolution passed through Postal Ballot in connection with making investments by way of subscription of shares in Saamya Biotech (Malaysia) Sdn. Bhd.

**10. GENERAL SHAREHOLDERS INFORMATION****(i) Annual General Meeting**

Date and Time	Wednesday, the 30th September, 2009 at 4.00 p.m.
Venue	Sundaraiah Vignana Kendram, (Mini Hall), Bagh Lingampally, Hyderabad - 500 044

(ii) Financial Calendar for the Year 2009-10 (tentative)

Financial reporting for the quarter ended	Before end of
June 30, 2009	July 2009
September 30, 2009	October 2009
December 31, 2009	January 2010
March 31, 2010	April 2010
AGM for the year ending March 31, 2010	September 2010
Dividend payment	The final dividend, if declared, shall be paid / credited within the statutory period.

(iii) Book Closure Dates : 25.09.2009 to 30.09.2009 (both days inclusive)

(iv) Listing on Stock Exchanges: The Bombay Stock Exchange Limited (BSE), Mumbai

(v) Listing fee: The Company has paid the listing fee for the financial year 2009-10

(vi) Stock Code:

Exchange	Script Code	Script ID
Bombay Stock Exchange Limited (BSE)	532905	SAAMYABIO

(vii) ISIN Code : INE320H01019

(viii) Stock Market Data

Bombay Stock Exchange Limited, Mumbai.		
Share Prices (In Rs.)		
Month	High	Low
April '08	14.23	11.05
May '08	13.75	10.22
June '08	10.85	8.00
July '08	9.49	7.00
August '08	10.70	8.22
September '08	9.99	7.10
October '08	9.15	3.71
November '08	7.14	4.07
December '08	5.75	4.20
January '09	6.84	4.40
February '09	5.60	4.01
March '09	4.95	3.57



Monthly High/Low of Market price of the Company's shares traded in BSE during the period from April, 2008 to March, 2009 is furnished above.

(ix) Share Transfer Agents

Aarathi Consultants Private Limited, whose address is given below, is the Share Transfer Agent of the Company for looking after the work related to share registry.

Contact Person: **Mr. G. Bhaskar**, Manager
 Aarathi Consultants Private Limited,
 1-2-285, Domalguda, Hyderabad – 500 029. A.P. India.
 Phone: +91-40-27634445, 27638111, 27642217, 66611921
 Fax : +91-40-27632184, Email: info@aarthiconsultants.com
 Website: www.aarthiconsultants.com

(x) Share Transfer System

The shareholders are advised to contact the Share Transfer Agents at their address for effecting transfer of shares or other matters related to shares held in physical mode. All correspondence relating to share transfers, transmission, dematerialization, dividends, and change of address can also be made at the above address.

(xi) (a) Distribution of Shareholding as on March 31, 2009 :

Nominal Value of Shareholding (in Rs.)	No. of Shareholders	Percentage	No. of Shares	Percentage
Up to 5,000	10,527	70	31,41,375	13.60
5,001 - 10,000	2,373	16	21,60,721	9.36
10,001 – 20,000	1,029	7	16,96,428	7.35
20,001 – 30,000	369	3	9,78,935	4.24
30,001 – 40,000	166	1	6,00,899	2.60
40,001 – 50,000	188	1	9,09,807	3.94
50,001 – 1,00,000	187	1	14,35,811	6.22
1,00,001 and above	146	1	1,21,68,524	52.69
TOTAL	14,985	100	2,30,92,500	100.00

(b) Categories of Shareholders as on March 31, 2009:

Category of Shareholder	Total Number of shares	Percentage	Shares pledged or otherwise encumbered	
			Number of Shares	As a percentage
Shareholding of Promoter and Promoter Group				
Indian	8079600	34.99		
Foreign	—	—	—	—
Total Shareholding of Promoter and Promoter Group	8079600	34.99	—	—



Category of Shareholder	Total Number of shares	Percentage	Shares pledged or otherwise encumbered	
Public Shareholding			—	—
Bodies Corporate	1647178	7.13	—	—
Individuals	—	—	—	—
i. Individual shareholders holding nominal share capital up to Rs.1 lakh	10357356	44.85	—	—
ii. Individual shareholders holding nominal share capital in excess of Rs.1 lakh	2642155	11.44	—	—
Others : -				
a) Non Resident Individuals	355729	1.54	—	—
b) Clearing Members	10482	0.05	—	—
Total Public Shareholding	15012900	65.01	—	—
Total	23092500	100.00	—	—
Grand Total (A)+(B)+(C)	23092500	100.00	—	—

(xii) Dematerialization of Shares and Liquidity

Since the Company has entered into an agreement with both the depositories namely NSDL and CDSL for dematerialization of its shares, the shareholders of the company have the choice to get dematerialize their shares and keep them in dematerialized form with either of the depository participants.

(xiii) Outstanding GDRs / ADRs / Warrants or any Convertible instruments, conversion date and likely impact on equity.

No such instruments have been issued by the Company.

(xiv) Address for Correspondence

Registered Office:
Suite No. 104-106,
Lumbini Enclave,
Punjagutta,
Hyderabad –500 082
Phone:040-23399241
Fax: 040-23395214
email: info@saamyabiotech.com
website: www.saamyabiotech.com

Corporate Office:
Plot No.391D, Road No.81
Jubilee Hills House Building Society
Phase III, Jubilee Hills
Hyderabad - 500 096.
Phone:040-23551601/04
Fax: 040-23541127

(xv) Plant Locations (Under Construction):

Plot No.9 & 10, Phase II, SP Biotech Park, Turkapalli, Shameerpet Mandal, Hyderabad



CERTIFICATE FROM MANAGING DIRECTOR FOR COMPLIANCE WITH CODE OF CONDUCT FOR BOARD AND SENIOR MANAGEMENT

This is to certify that M/s. Saamya Biotech (India) Limited has put in place the Code of Conduct for the Board of Directors and Senior Management. This code is applicable to all the Directors of the Company and the Members of Senior Management, which includes the employees of the Company who are one level below the Whole time Directors and all the functional heads. The Directors and Members of Senior Management have affirmed compliance with the Code of Conduct for the Board of Directors and Senior Management as on March 31, 2009. The Company has complied with the provisions of the Listing Agreement in this respect.

For Saamya Biotech (India) Limited

Date: Hyderabad
Place: 31-08-2009

Dr. Y. Manivardhan Reddy
Managing Director

CERTIFICATE BY THE CHIEF EXECUTIVE OFFICER (CEO) AND CHIEF FINANCIAL OFFICER (CFO)

I, **Dr. Y. Manivardhan Reddy**, Managing Director of M/s. Saamya Biotech (India) Limited certify:

1. That we have reviewed the financial statements and the cash flow statement for the year ended 31st March 2009 and to the best of our knowledge and belief;
 - a) These statements do not contain any materially untrue statement nor omit any material fact nor contain statements that might be misleading, **and**
 - b) These statements present a true and fair view of the company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
2. That there are, to the best of our knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violative of the company's code of conduct;
3. That we accept responsibility for establishing and maintaining internal controls, we have evaluated the effectiveness of the internal control systems of the company and we have disclosed to the auditors and the audit committee, deficiencies in the design or the operation of internal controls, if any, of which we are aware and the steps that we have taken or propose to take and rectify the identified deficiencies and;
4. That we have informed the auditors and the audit committee of:
 - a) Significant changes in the internal control during the year;
 - b) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c) Instances of significant fraud of which we have become aware and the involvement of any employee having a significant role in the company's internal control system.

Place : Hyderabad
Date : 31.08.2009

Dr. Y. Manivardhan Reddy
Managing Director



COMPLIANCE CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members of
Saamya Biotech (India) Limited
Hyderabad

We have read the report of the Board of Directors on Corporate Governance and have examined the relevant records relating to compliance condition of corporate governance of Saamya Biotech (India) Limited ("the company") for the year ended 31st March, 2009 as stipulated in clause 49 of the listing agreement of the said company with the Stock Exchanges.

The compliance of the conditions of the corporate governance is the responsibility of the management. Our examination, conducted in the manner described in the Guidance note on "Certification of Corporate Governance" issued by the Institute of Chartered Accountants of India was limited to procedures and implementation thereof adopted by the company for ensuring compliance with the conditions of Corporate Governance. Our examination was neither an audit nor was it conducted to express an opinion on the financial statements of the company.

In our opinion and to the best of our information and explanations given to us and on the basis of our examination described above, the company has complied with the conditions of Corporate Governance as stipulated in clause 49 of the above mentioned Listing Agreement.

We further state that such compliance is neither an assurance as to the future viability of the company nor the efficiency or effectiveness with which the management has conducted the affairs of the company.

For P. Murali & Co.,
Chartered Accountants

P. Murali Mohana Rao
Partner

Place: Hyderabad
Date: 31-08-2009



AUDITORS' REPORT

To
The Members,

SAAMYA BIOTECH (INDIA) LIMITED

We have audited the attached Balance Sheet of Saamya Biotech (India) Limited as at 31st March, 2009 and the cash flow statement for the period ended on that date. These financial statements are the responsibility of the Company's Management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether; the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statement. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall statement presentation. We believe that our audit provides a reasonable basis of our opinion.

As required by the Companies (Auditor's report) order 2003 and as amended by the Companies (Auditor's report) (Amendment) order 2004, issued by the Central Government of India in terms of the sub-section (4A) of section 227 of the Companies Act, 1956, we enclose in the annexure a statement on the matters specified in paragraphs 4 and 5 of the said order.

Further to our comments in the annexure referred to above, we report that:

- (i) We have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (ii) In our opinion, proper books of account as required by law have been kept by the company so far as appears from our examination of those books;
 - (iii) The balance sheet dealt with by this report are in agreement with the books of account;
 - (iv) In our opinion, the balance sheet dealt with by this report comply with the Accounting standards referred to in sub-section (3C) of section 211 of Companies Act, 1956;
 - (v) On the basis of written representations received from the Directors, as on 31st March, 2009 and taken on record by the Board of Directors, we report that none of the Directors is disqualified as on 31st March, 2009 from being appointed Director in terms of clause(g) of sub-section(1) of section 274 of Companies Act, 1956;
 - (vi) In our opinion and to the best of our information and according to the explanations given to us, the said accounts give the information required by the Companies Act, 1956, in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:
- (a) In the case the balance sheet, of the state of affairs of the Company as at 31st March, 2009;

And

- (b) In the case of Cash Flow statement, of the cash flows for the period ended on that date:

For P. Murali & Co.,
Chartered Accountants

Place: Hyderabad
Date: 31-08-2009

Sd/-
Partner



ANNEXURE TO THE AUDITORS' REPORT

- I. (a) The Company has maintained proper records showing full particulars including quantitative details and situation of Fixed Assets.
- (b) As explained to us, the fixed assets have been physically verified by the management at reasonable intervals and no material discrepancies between the book records and the physical inventory have been noticed on such verification.
- (c) The company has not disposed off substantial part of the fixed assets during the year.
- II. The company has no Inventory. Hence this clause is not applicable.
- III. (a) The Company has not granted any loans, secured or unsecured to Companies, Firms or other parties covered in the register maintained U/s.301 of Companies Act, 1956.
- (b) The Company has not granted any loans, the clause of whether the rate of interest & other terms and conditions on which loans have been granted to parties listed in the register maintained under section 301 is prejudicial to the interest of the company, is not applicable.
- (c) As no loans are granted by company, the clause of receipt of interest & principal amount from parties is not applicable to the company.
- (d) No loans have been granted to Companies, Firms & other parties listed in the register U/s. 301 of the Companies Act, 1956, hence overdue amount of more than rupees one lakh does not arise and the clause is not applicable.
- (e) The Company has not taken any loans, secured or unsecured from companies, Firms or other parties covered in the register maintained U/s.301 of the Companies Act, 1956.
- (f) As the Company has not taken any loans, the clause of whether the rate of interest & other terms and conditions on which loans have been taken from parties listed in the register maintained under section 301 is prejudicial to the interest of company, is not applicable.
- (g) As no loans are taken by the company, the clause of repayment of interest & principal amount to parties is not applicable to the company.
- IV. In our opinion and according to the information and explanations given to us, there are generally adequate internal control systems commensurate with the size of company and the nature of its business with regard to purchase of fixed assets and for sale of goods and services. There is no continuing failure by the company to correct any major weaknesses in internal control.
- V. (a) In our opinion and according to the information and explanation give to us, since no contracts or arrangements referred to in section 301 of the Companies Act,



1956 have been made by the company in respect of any party in the financial year, the entry in the register U/s. 301 of the Companies Act, 1956 does not arise.

- (b) According to the information and explanations give to us, as no such contracts or arrangements made by the company, the applicability of the clause of charging the reasonable price having regard to the prevailing market prices at the relevant time does not arise.
- VI. The Company has not accepted any deposits from the public and hence the applicability of the clause of directives issued by the Reserve Bank of India and provisions of section 58A, 58AA or any other relevant provisions of the Act and the rules framed there under does not arise. As per information and explanations given to us the order from the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Court or any other Tribunal has not been received by the Company.
- VII. In our opinion, the company is having internal audit system, commensurate with its size and nature of its business.
- VIII. In respect of the Company, the Central Government has not prescribed maintenance of cost records under clause (d) of sub-section (1) of section 209 of the Companies Act, 1956.
- IX. (a) The Company is regular in depositing statutory dues including and any other statutory dues with the appropriate authorities and at the last of the financial year there were no amounts outstanding which were due for more than 6 months from the date they became payable.
- (b) According to the information and explanations given to us, no undisputed amounts are payable in respect of and any other statutory dues as at the end of the period, for a period more than six months from the date they became payable.
- X. The company has been registered for a period of not less than 5 years, and since the company has not started its commercial operations, this clause is not applicable.
- XI. According to information and explanations given to us, the Company has not defaulted in repayment of dues to financial institutions or banks.
- XII. According to the information and explanations given to us, the company has not granted any loans or advance on the basis of security by way of pledge of shares, debentures and other securities and hence the applicability of the clause regarding maintenance of adequate documents in respect of loans does not arise.
- XIII. This clause is not applicable to this company as this company is not covered by the provisions of special status applicable to Chit Fund in respect of Nidhi / Mutual Benefit Fund / Societies.
- XIV. According to the information and explanations given to us, the company is not dealing or trading in shares, securities, debentures and other investments and hence the provisions of clause 4(xiv) of the Companies (Auditor's Report) order 2003, are not applicable to the company.



- XV. According to the information and explanations given to us, the company has not given any guarantee for loans taken by others from banks or financial institutions, and hence the applicability of this clause regarding terms and conditions which are prejudicial to the interest of the company does not arise.
- XVI. According to the information and explanations given to us, the company has not obtained any term loans; hence this clause is not applicable.
- XVII. According to the information and explanations given to us, no funds are raised by the company on short-term basis. Hence the clause of short term funds being used for long-term investment does not arise.
- XVIII. According to the information and explanations given to us, the company has not made any preferential allotment of shares to parties and companies covered in the Register maintained under section 301 of the Companies Act, 1956 and hence the applicability of the clause regarding the price at which shares have been issued and whether the same is prejudicial to the interest of the Company does not arise.
- XIX. According to the information and explanations given to us, the company does not have any debentures and hence the applicability of the clause regarding the creation or security or charge in respect of debentures issued does not arise.
- XX. We have verified the end use of money raised by public issues as disclosed in the notes to the financial statements.
- XXI. According to the information and explanations given to us, no fraud on or by the company has been noticed or reported during the year under audit.

For P. MURALI & CO.,
Chartered Accountants

Place: Hyderabad
Date: 31-08-2009

P. Murali Mohana Rao
Partner



BALANCE SHEET AS AT 31ST MARCH, 2009

(Rupees)

	Sch. No.	Year Ended 31-03-2009	As At 31-03-2008
I. SOURCE OF FUNDS			
1. SHAREHOLDERS FUNDS			
a. Share Capital	1	230,925,000	230,925,000
b. Share Application Money		14,115,035	15,049,305
2. LOAN FUNDS			
a. Secured Loans	2	1,146,133	9,232,953
b. Unsecured Loans		-	782,511
TOTAL		<u>246,186,168</u>	<u>255,989,769</u>
II. APPLICATION OF FUNDS			
1. FIXED ASSETS			
a. Gross Block	3	7,004,518	6,128,664
2. INVESTMENTS			
	4	68,323	82,304,180
3. CURRENT ASSETS, LOANS & ADVANCES			
a. Cash & Bank Balance	5	538,257	1,831,630
b. Loans, Advances & Deposits	6	164,791,100	130,428,500
c. Pre-operative Expenses pending for allocation		75,114,940	37,835,829
Less: Current Liabilities & Provisions	7	1,628,059	2,836,122
NET CURRENT ASSETS		238,816,238	167,259,837
4. MISCELLANEOUS EXPENDITURE (to the extent not written off or adjusted)			
		297,089	297,089
NOTES ON ACCOUNTS	8	-	-
TOTAL		<u>246,186,168</u>	<u>255,989,769</u>

As per our report of even date
For **P. MURALI & CO.**,
CHARTERED ACCOUNTANTS

For and on behalf of the Board
For **SAAMYA BIOTECH (INDIA) LIMITED**

P. Murali Mohana Rao
Partner

Dr. Y. Manivardhan Reddy
Managing Director

Dr. Y. Sonia Reddy
Vice Chairman &
Joint Managing Director

Place: Hyderabad
Date: 31-08-2009

**SCHEDULES FORMING PART OF THE ACCOUNTS AS AT 31ST MARCH, 2009**

(Rupees)

PARTICULARS	As At 31-03-2009	As At 31-03-2008
SCHEDULE - 1		
SHARE CAPITAL		
AUTHORISED		
25,000,000 Equity shares of Rs.10/-each	<u>250,000,000</u>	<u>250,000,000</u>
ISSUED, SUBSCRIBED AND PAID UP:		
23,092,500 Equity shares of Rs.10/-each	230,925,000	230,925,000
TOTAL	<u>230,925,000</u>	<u>230,925,000</u>
SCHEDULE - 2		
SECURED LOANS		
Over Draft Facility with HDFC Bank against Securities	-	6,767,633
Finance from Banks/Financial Institutions for Vehicles, Computers (Against hypothecation of vehicles/Computers)	1,146,133	2,465,320
TOTAL	<u>1,146,133</u>	<u>9,232,953</u>
SCHEDULE - 3		
FIXED ASSETS		
Furniture & Fixtures	562,633	541,019
Office Equipments	1,241,923	627,573
Vehicle	3,122,051	3,122,051
Computers	2,077,911	1,838,021
TOTAL	<u>7,004,518</u>	<u>6,128,664</u>
SCHEDULE - 4		
INVESTMENTS		
Fixed Deposit with Scheduled Bank	-	10,000,000
Liquid Funds with Banks/Financial Institutions	68,323	72,304,180
TOTAL	<u>68,323</u>	<u>82,304,180</u>



SCHEDULES FORMING PART OF THE ACCOUNTS AS AT 31ST MARCH, 2009

(Rupees)

PARTICULARS	As At 31-03-2009	As At 31-03-2008
SCHEDULE - 5		
CASH & BANK BALANCES		
Cash in Hand	398,477	377,449
Bank Balance with Schduled Bank		
a. Current Accounts	74,780	454,911
b. Others - IPO Refund Account	65,000	999,270
TOTAL	<u>538,257</u>	<u>1,831,630</u>
SCHEDULE - 6		
LOANS, ADVANCES & DEPOSITS		
Loans & Advances		
a. Advance for Capital Goods	112,000,000	112,000,000
b. Advance for Land & Building	26,902,000	11,202,000
c. TDS Receivable	1,185	-
d. Other Advances	24,286,075	5,722,000
Deposits (Including Deposit with BSE)	1,601,840	1,504,500
TOTAL	<u>164,791,100</u>	<u>130,428,500</u>
SCHEDULE - 7		
CURRENT LIABILITIES & PROVISIONS		
Sundry Creditors	355,996	67,886
Provisions & Outstanding Expenses	1,272,063	2,768,236
TOTAL	<u>1,628,059</u>	<u>2,836,122</u>

**SCHEDULE-8****NOTES FORMING PART OF THE ACCOUNTS****A. SIGNIFICANT ACCOUNTING POLICIES****General:**

- (i) These accounts are prepared on the historical cost basis and on the accounting principles of going concern.
- (ii) Accounting policies not specifically referred to otherwise or consistent and in consonance with generally accepted accounting principles.

Revenue Recognition:

The Company follows the mercantile system of Accounting and recognizes income and expenditure on accrual basis.

Investments:

Investments are valued at cost or market price which ever is lower.

Fixed Assets:

Fixed assets are stated at cost. Cost of acquisition of fixed assets is inclusive of freight, duties, taxes and incidental expenses thereto.

Depreciation:

The company has not stated the commercial production hence the depreciation is not provided.

Taxation:

The current charge for income tax is calculated in accordance with the relevant tax regulations applicable to the company. Deferred tax asset and liability is recognized for future tax consequences attributable to the timing difference that result between the profit offered for income tax and the profit as per the financial statements. Deferred tax asset and liability are measured as per the tax rates/laws that have been enacted or substantively enacted by the Balance Sheet date.

Gratuity:

The company has not made any provision for gratuity to its employees, because no employees has put it qualifying period of service for entitlement of this benefit.

Earnings per Share:

The earning considered in ascertaining the company's earning per share comprises net profit after tax. The number of shares used in computing basic earning per share is the weighted average number of shares outstanding during the year.

B. NOTES OF ACCOUNTS

1. Particulars of Employees in accordance with sub-section (2A) of section 217 of the Companies Act, 1956 read with Companies (Particulars of Employees) Rule 1975.

	Current Year(Rs.)	Previous Year(Rs.)
2. Managerial Remuneration	Nil	Nil
Director's Remuneration	59,50,689/-	22,30,300/-
3. Auditor's Remuneration		
Audit Fee	55,150/-	56,180/-



4. Detailed information regarding quantitative particulars under part II of Schedule VI to the Companies Act, 1956.

The Company has not started the commercial production hence the quantitative particulars are not possible.

5. Earnings and Expenditure of Foreign Exchange as reported by the Company to the Government of India and as certified by the management.

	Current Year(Rs.)	Previous Year(Rs.)
(i) Foreign exchange Earnings	Nil	Nil
(ii) Foreign exchange Outgo	109,67,283/-	44,88,446/-
6. Travel Expenditure		
Foreign Travel	12,98,503/-	5,56,045/-

7. There are no dues to SSI Units outstanding for more than 30 days.
 8. Confirmations were obtained from debtors / creditors as to the balances receivable from / payable to them as at year end.

9. Deposits:

Include Rs. 15,00,000/- made to Bombay Stock Exchange Limited for ensuring compliance for all the listing requirements. This amount is refundable on compliance of the said requirements and after furnishing No Objection Certificates from the Securities & Exchange Board of India.

10. Secured Loans:

Company has taken the Vehicle / Equipment loans from the Banks / financial institutions are secured against hypothecation of vehicles / equipments.

11. Deferred Tax:

In accordance with Accounting Standard 22 (As 22) issued by the ICAI, the Company has no differ tax liability during the year, hence differ tax liability has not been provided.

12. Loan & Advances:

Includes advance for plant & Machinery of Rs. 1120.00 lakhs and Land & Building of Rs. 269.02 lakhs.

13. The Earning Per Share:

The Company has not started the commercial production; hence the Earning Per Share is not applicable in this year.

14. Previous year's figures have been regrouped wherever necessary.

15. The figures have been rounded off to the nearest rupee.

SIGNATURES TO SCHEDULES 1 TO 8

**As per our report of even date
 For P. MURALI & CO.,
 CHARTERED ACCOUNTANTS**

**For and on behalf of the Board
 SAAMYA BIOTECH (INDIA) LIMITED**

P. Murali Mohana Rao
 Partner

Dr. Y. Manivardhan Reddy
 Managing Director

Dr. Y. Sonia Reddy
 Vice Chairman &
 Joint Managing Director

Place: Hyderabad
 Date: 31-08-2009

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31-03-2009**

(Rupees)

PARTICULARS	Year Ended 31-03-2009	Year Ended 31-03-2008
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before taxation, and extraordinary items	NIL	NIL
Adjustments for:		
Finance Cost	--	--
Misc. Expenses Written off	--	--
Depreciation	--	--
Operating Profit before working capital change		
Trade and other receivables	--	--
Increase in current liabilities & provisions	(1,208,063)	2,500,712
Increase in Preoperative Expenses	(37,279,111)	(24,749,257)
Cash generated from operations	(38,487,174)	(22,248,545)
Interest paid	--	--
Cash flow before extraordinary items	(38,487,174)	(22,248,545)
Extraordinary items	--	--
NET CASH FLOW FROM OPERATING ACTIVITIES	<u>(38,487,174)</u>	<u>(22,248,545)</u>
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase / Sale of Fixed Assets	(875,854)	(2,668,088)
Increase in Loans & Advances	(34,362,600)	(51,486,668)
Increase in Investments	82,235,856	(82,304,180)
NET CASH USED IN INVESTING ACTIVITIES	<u>46,997,402</u>	<u>(136,458,936)</u>
C. CASH FLOW FROM FINANCING ACTIVITIES:		
Proceeds from Equity Shares	--	150,125,000
Proceeds from share application money	(934,270)	5,969,185
Proceeds from secured Loans	(8,086,820)	7,632,115
Proceeds from unsecured Loans	(782,511)	(3,282,854)
NET CASH FLOW FROM FINANCING ACTIVITIES	<u>(9,803,601)</u>	<u>160,443,446</u>
NET INCREASE \ (DECREASE) IN CASH AND CASH EQUIVALENTS	<u>(1,293,373)</u>	<u>1,735,965</u>
Cash and Cash equivalents (Opening Balance)	1,831,630	95,665
Cash and Cash equivalents (Closing Balance)	<u>538,257</u>	<u>1,831,630</u>

For and on behalf of the Board
SAAMYA BIOTECH (INDIA) LIMITED

Place: Hyderabad
Date: 31-08-2009

Dr. Y. Manivardhan Reddy
Managing Director

Dr. Y. Sonia Reddy
Vice Chairman &
Joint Managing Director



CERTIFICATE

To
The Board of Directors
Saamya Biotech (India) Limited
Hyderabad.

We have examined the attached Cash Flow Statement of M/s. Saamya Biotech (India) Limited for the year ended 31st March, 2009. The Statement has been prepared by the company in accordance with the requirement of Clause 32 of listing agreement with Stock Exchange and is based on and in agreement with the corresponding Balance Sheet of the Company covered by our report of 31st August, 2009 to the members of the company.

Yours faithfully,
For P. MURALI & CO.,
CHARTERED ACCOUNTANTS

P.MURALI MOHANA RAO
PARTNER

PLACE: HYDERABAD
DATE : 31-08-2009



**Statement Pursuant to part IV of Schedule VI to the Companies Act, 1956:
Balance Sheet Abstract and Company's General Business Profile**

I. Registration Details

Registration No. State Code

Balance Sheet Date

Date Month Year

II. Capital Raised during the Year (Amount in Rs. Thousands)

Public Issue

Right Issue

Bonus Issue

Private Placement

III. Position of Mobilisation and Deployment of Funds (Amount in Rs.Thousands)

Total Liabilities

Total Assests

Sources of Funds

Paid-up Capital

Share Application Money

Secured Loans

Unsecured Loans

Application of Funds

Net Fixed Assets

Investments

Net Current Assets

Misc. Expenditure

Accumulated Losses

Deferred Income Tax Assets

IV. Performance of Company (Amount in Rs. Thousands)

Turnover

Total Expenditure

Profit/ Loss Before Tax

Profit/ Loss After Tax

Earning Per Share in Rs.

Dividend rate %

V. Generic Names of Three Principal Products / Services of Company

Item Code No.
(ITC Code)

Product Description: BIO-CHEMIC PHARMACEUTICALS

7th Annual General Meeting
SAAMYA BIOTECH (INDIA) LIMITED

Regd.Office:104-106, Lumbini Enclave, Punjagutta, Hyderabad - 500 082.

ADMISSION SLIP

Date

30th September, 2009

Venue

Sundaraiah Vignana Kendram
(Mini Hall), Bagh Lingampally,
Hyderabad – 500 044

Time

4.00 pm

Name of the shareholder	Folio no. / DPID and Client ID	No. of shares

I certify that I am a registered shareholder of the Company and hold above-mentioned shares in the Company and hereby record my present at the 7th Annual General Meeting of the Company.

Member's/Proxy signature

Note: Shareholder/Proxy holder wishing to attend the meeting must bring the Admission Slip and hand over at the entrance duly signed.

7th Annual General Meeting
SAAMYA BIOTECH (INDIA) LIMITED

Regd.Office:104-106, Lumbini Enclave, Punjagutta, Hyderabad - 500 082.

Proxy Form

Regd. Folio no.:..... No. of shares.....

DP ID no. Client ID no.....

I / We _____ of _____ being
Member / Members of Saamy Biotech (India) Limited hereby appoint


_____ of _____ as my / our
proxy to attend and vote for me/us on my / our behalf at the 7th Annual General Meeting of the Company to be held on Wednesday, 30th September 2009 at 4.00 p.m. at Sundaraiah Vignana Kendram, (Mini Hall), Bagh Lingampally, Hyderabad – 500 044 and at any adjournment thereof.


As witness my/our hand (s) this _____ day of _____ of 2009

Signed by the said _____

Affix
Re1/-
Revenue
Stamp

Signature





Book-Post

To,



Saamya Biotech (India) Ltd.

Suite 104-106, Lumbini Enclave
Opp: NIMS, Punjagutta, Hyderabad 500 082, A.P., INDIA.
Tel: +91-40-23398359, 23399241 Fax: +91-40-23395241
E-mail: saamyaindia@saamyabiotech.com

Website : www.saamyabiotech.com